26 June 2024
Avacta Group plc
("Avacta" or the "Group" or the "Company")
Result of Annual General Meeting
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, is pleased to announce that all resolutions have been duly passed (with the exception of Resolution 6 which was not put to the meeting) by shareholders at the Annual General Meeting held today.
The full text of each resolution is set out in the Notice of Annual General Meeting, which is available under the Investor Resources section of the Company's website https://avacta.com/investors/investor-resources/. All presentation materials available to shareholders, including slide decks and a video presentation by Chris Coughlin, will also be posted at the same link as above by the end of the day.
-Ends-
For further information from Avacta Group plc, please contact:
| Avacta Group plc Christina Coughlin, CEO Tony Gardiner, Chief Financial Officer Michael Vinegrad, Group Communications Director
| Tel: +44 (0) 1904 21 7070 |
| | |
| Peel Hunt (Nomad and Broker) James Steel / Chris Golden / Patrick Birkholm
|
|
| ICR Consilium Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji |
|
About Avacta Group plc - www.avacta.com
Avacta Group is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics.
Avacta Therapeutics: a clinical stage oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs.
Avacta Diagnostics focuses on supporting healthcare professionals and broadening access to diagnostics.
Avacta has two proprietary platforms, pre|CISION™ and Affimer®.
The pre|CISION™ platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumours compared with healthy tissues. The pre|CISION™ platform harnesses this tumour specific protease to activate pre|CISION™ peptide drug conjugates and pre|CISION™ antibody/Affimer® drug conjugates in the tumour microenvironment, reducing systemic exposure and toxicity, allowing dosing to be optimised to deliver the best outcomes for patients.
The lead pre|CISION™ programme AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies. It has shown an improvement in safety and tolerability in clinical trials to date compared with standard doxorubicin and preliminary signs of clinical activity in multiple patients.
To register for news alerts by email go to www.avacta.com/investor-news-email-alerts
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
